CEL-SCI Corporation (NYSE MKT:CVM) announced today it has held the Investigator Meeting for the European clinical investigators participating in the ongoing Phase III clinical trial of CEL-SCI’s investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Inj.).
Help employers find you! Check out all the jobs and post your resume.
